EA200801287A1 - Пиримидиновые производные для лечения аномального клеточного роста - Google Patents

Пиримидиновые производные для лечения аномального клеточного роста

Info

Publication number
EA200801287A1
EA200801287A1 EA200801287A EA200801287A EA200801287A1 EA 200801287 A1 EA200801287 A1 EA 200801287A1 EA 200801287 A EA200801287 A EA 200801287A EA 200801287 A EA200801287 A EA 200801287A EA 200801287 A1 EA200801287 A1 EA 200801287A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
cell growth
pyrimidine derivatives
anomalous cell
mammals
Prior art date
Application number
EA200801287A
Other languages
English (en)
Other versions
EA014551B1 (ru
Inventor
Джоэль Томас Эркари
Самит Кумар Бхаттачарья
Артур Дуглас Бросиус
Майкл Джозеф Луццио
Кендра Луиз Нельсон
Гонгхуа Пан
мл. Саутерс Джеймс Альфред
Донн Грегори Уишка
Джун Ксьяо
Original Assignee
Пфайзер Продактс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс, Инк. filed Critical Пфайзер Продактс, Инк.
Publication of EA200801287A1 publication Critical patent/EA200801287A1/ru
Publication of EA014551B1 publication Critical patent/EA014551B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (I) или его фармацевтически приемлемой соли, где Аr представляет собой группу (III). Такие пиримидиновые производные полезны в лечении аномального клеточного роста, такого как рак, у млекопитающих. Это изобретение также относится к способу применения таких соединений в лечении аномального клеточного роста у млекопитающих, в особенности людей, и к фармацевтическим композициям, содержащим такие соединения.
EA200801287A 2005-12-21 2006-12-11 Пиримидиновые производные для лечения аномального клеточного роста EA014551B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21
PCT/IB2006/003655 WO2007072158A2 (en) 2005-12-21 2006-12-11 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
EA200801287A1 true EA200801287A1 (ru) 2008-10-30
EA014551B1 EA014551B1 (ru) 2010-12-30

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801287A EA014551B1 (ru) 2005-12-21 2006-12-11 Пиримидиновые производные для лечения аномального клеточного роста

Country Status (30)

Country Link
US (1) US7820648B2 (ru)
EP (1) EP1966207A2 (ru)
JP (1) JP4332590B2 (ru)
KR (1) KR101060051B1 (ru)
CN (1) CN101346380B (ru)
AP (1) AP2008004488A0 (ru)
AR (1) AR058399A1 (ru)
AU (1) AU2006327871A1 (ru)
BR (1) BRPI0620324A2 (ru)
CA (1) CA2634646C (ru)
CR (1) CR10095A (ru)
DO (1) DOP2006000289A (ru)
EA (1) EA014551B1 (ru)
EC (1) ECSP088563A (ru)
GT (1) GT200600517A (ru)
HN (1) HN2006042221A (ru)
IL (1) IL191555A0 (ru)
MA (1) MA30075B1 (ru)
ME (1) MEP0908A (ru)
NL (1) NL2000375C2 (ru)
NO (1) NO20082338L (ru)
PE (1) PE20071138A1 (ru)
RS (1) RS20080272A (ru)
SV (1) SV2008002969A (ru)
TN (1) TNSN08270A1 (ru)
TW (1) TW200736258A (ru)
UA (1) UA89123C2 (ru)
UY (1) UY30051A1 (ru)
WO (1) WO2007072158A2 (ru)
ZA (1) ZA200804488B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP2041132A2 (en) * 2006-07-06 2009-04-01 Boehringer Ingelheim International GmbH New compounds
WO2008051547A1 (en) 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
EA016679B1 (ru) 2007-04-18 2012-06-29 Пфайзер Продактс Инк. Сульфониламидные производные для лечения аномального роста клеток
BRPI0814432A2 (pt) * 2007-07-17 2017-05-09 Rigel Pharmaceuticals Inc pirimidinadiaminas substituídas por amina cíclica como inibidores de pkc
EP2231620A1 (en) * 2007-12-03 2010-09-29 Boehringer Ingelheim International GmbH Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011515372A (ja) * 2008-03-20 2011-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリミジン類の位置選択的製造法
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
ES2472323T3 (es) 2008-06-17 2014-06-30 Astrazeneca Ab Compuestos de piridina
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
EP2571867B1 (en) 2010-05-21 2015-11-04 Noviga Research AB Novel pyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
PL2646448T3 (pl) 2010-11-29 2017-12-29 OSI Pharmaceuticals, LLC Makrocykliczne inhibitory kinazy
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2013083206A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
KR20140114344A (ko) 2011-12-23 2014-09-26 셀좀 리미티드 키나제 억제제로서의 피리미딘-2,4-디아민 유도체
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
EP3484528B1 (en) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Tau pet imaging ligands
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
JP2024502174A (ja) * 2021-01-07 2024-01-17 オンタリオ・インスティテュート・フォー・キャンサー・リサーチ（オーアイシーアール） Ｎｕａｋキナーゼの阻害剤としてのチエニル及びシクロアルキルアミノピリミジン化合物、その組成物及び使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EA200601796A1 (ru) * 2004-05-14 2007-04-27 Пфайзер Продактс, Инк. Пиримидиновые производные для лечения аномального клеточного роста
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
AP2008004488A0 (en) 2008-06-30
RS20080272A (en) 2009-07-15
AR058399A1 (es) 2008-01-30
BRPI0620324A2 (pt) 2011-11-08
UY30051A1 (es) 2007-07-31
US7820648B2 (en) 2010-10-26
JP4332590B2 (ja) 2009-09-16
SV2008002969A (es) 2010-08-17
WO2007072158A8 (en) 2008-08-14
TW200736258A (en) 2007-10-01
UA89123C2 (ru) 2009-12-25
GT200600517A (es) 2007-09-13
WO2007072158A2 (en) 2007-06-28
TNSN08270A1 (fr) 2009-10-30
CN101346380A (zh) 2009-01-14
CA2634646A1 (en) 2007-06-28
PE20071138A1 (es) 2007-12-29
WO2007072158A3 (en) 2007-12-27
US20080234303A1 (en) 2008-09-25
EA014551B1 (ru) 2010-12-30
ZA200804488B (en) 2009-05-27
NL2000375A1 (nl) 2007-06-25
MEP0908A (xx) 2010-02-10
EP1966207A2 (en) 2008-09-10
JP2009520807A (ja) 2009-05-28
NO20082338L (no) 2008-06-25
HN2006042221A (es) 2010-01-18
NL2000375C2 (nl) 2008-01-03
CA2634646C (en) 2012-04-10
CR10095A (es) 2008-07-17
KR20080077026A (ko) 2008-08-20
KR101060051B1 (ko) 2011-08-29
AU2006327871A1 (en) 2007-06-28
MA30075B1 (fr) 2008-12-01
DOP2006000289A (es) 2007-07-31
CN101346380B (zh) 2012-02-29
ECSP088563A (es) 2008-07-30
IL191555A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
EA200801287A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EA200601796A1 (ru) Пиримидиновые производные для лечения аномального клеточного роста
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
EA200971104A1 (ru) Производные бензимидазола
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009011090A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
DE602005004286D1 (de) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
WO2011027249A3 (en) Benzimidazole derivatives
MX2007013624A (es) Inhibidores de proteina cinasa.
SE0400284D0 (sv) Novel compounds
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
WO2007017728A3 (en) Novel heterocyclic compounds
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
MY153733A (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
TW200505869A (en) Thiophenylaminoimidazolines
EA200970496A1 (ru) Соединения 2-алкилиндазола для лечения некоторых расстройств цнс
UA93313C2 (en) Benzimidazole derivatives
EA202191818A1 (ru) 3-карбониламино-5-циклопентил-1h-пиразольные соединения, обладающие ингибирующей активностью в отношении cdk2
TH105256A (th) อนุพันธ์ไพริมิดีนสำหรับการรักษาการเจริญเติบโตของเซล์ที่ผิดปกติ

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU